U.S. FDA Sends Alogliptin Complete Response Letter To Takeda
This article was originally published in PharmAsia News
Executive Summary
U.S. FDA has issued a complete response letter to Takeda Pharmaceutical, and has requested additional data for its alogliptin and fixed-dose combination alogliptin and pioglitazone.